Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
In the IRA: Sold ALVIX, FMIEX is doing well enough. I'll likely flip the proceeds to VVOAX to get more SMID exposure. It also has ~9% foreign exposure versus ~7.25 for ALVIX.
Sold CBLDX. It hasn't been doing well in the recent environment. NRDCX will remain as my only junk fund.
Sold 90% of PRWCX. Not happy with that either. It holds a higher percentage of tech than FMILX, which is my designated growthier fund. I'm not excited by the rest of the equity allocation either. I thought about ditching it completely, but decided to allow some time for things to reorient.
With the proceeds I started a position in VVOAX and added to GLIFX, EISIX, FMIEX, and FMILX.
On the bond side I am looking at DFSD and SEBFX to replace GSST, VNLA, and HSDIX.
Switching out of PRCPX (TRP Junk) into SPHY (State Street Junk.) Schwab will not let you "sell and buy another" when you're dealing with two different species, like that. The solution is just to split it into two separate trades. I'm making the move into a lower ER in SPHY and a bit higher yield. 20.88% of the portfolio is involved, here.
Bought 500 NVO as it's down 15% on the Cagrisema news. "Patients taking a standard dose of CagriSema lost 20.2% of their body weight after 84 weeks, compared with 23.6% for Lilly’s tirzepatide." IMO that's still pretty damn good.
Also buried in the drama is they received EU aproval for 7.2mg Wegovy dosages, which I take as a good thing since Wegovy is cheaper than Zepbound for obesity.
Are software stocks ever going to stop dropping? I keep thinking they cannot go any further, and each day they sink more.
The two that I hold, that are annoying me greatly, are TRI and ADBE. I understand this is about AI fears to their business models, But, surely they cannot be worth 40-50% less than they were, mere months ago. If I wasn't already smarting from owing them, I'd consider this a buying opportunity of epic proportions.
I just KNOW that as soon as I dump them, they rebound considerably.
Big jump up for both TRI (+12%) and ADBE (+3.25%). Maybe software stocks have hit bottom and the carnage is over?
In the IRA: Sold out HSDIX and remaining position in PRWCX. Sold out VNLA and GSST where I was stashing some cash.
At the moment the plan is to buy FEUNX and more--or less--add to existing positions in MGOIX, NRDCX, THOPX and JPIB. There will also be some funds available to boost the equity portion towards 30%.
We shall see how I'll feel about all of that come Monday morning. Bonds are currently rallying, but can that persist in the face of the PPI report? Reply hazy. Ask again later.
Bought 1000s BIPI for qualified dividend income, which drops available cash down to maybe 1-2 more purchases. I'll then be moving 80% or so from PRWCX to continue picking up dividend paying equities and other items of interest.
Comments
On the bond side I am looking at DFSD and SEBFX to replace GSST, VNLA, and HSDIX.
Thanks for that.
Sold AJG, FLO, CNS
(Basket down to 20 holdings)
Schwab will not let you "sell and buy another" when you're dealing with two different species, like that. The solution is just to split it into two separate trades. I'm making the move into a lower ER in SPHY and a bit higher yield. 20.88% of the portfolio is involved, here.
Also buried in the drama is they received EU aproval for 7.2mg Wegovy dosages, which I take as a good thing since Wegovy is cheaper than Zepbound for obesity.
At the moment the plan is to buy FEUNX and more--or less--add to existing positions in MGOIX, NRDCX, THOPX and JPIB. There will also be some funds available to boost the equity portion towards 30%.
We shall see how I'll feel about all of that come Monday morning. Bonds are currently rallying, but can that persist in the face of the PPI report? Reply hazy. Ask again later.